Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delia Goletti

Showing results (31-40 of 310) with videos related to

Pageof 31
Sort By:
European Journal of Histochemistry : EJH|June 28, 2019
Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometryTonino Alonzi, Elisa Petruccioli, Valentina Vanini, et al.
Infectious Disease Reports|July 13, 2016
Tuberculosis Biomarkers: From Diagnosis to ProtectionDelia Goletti, Elisa Petruccioli, Simone A Joosten, et al.
Cytokine & Growth Factor Reviews|February 12, 2013
Autophagy in Mycobacterium tuberculosis infection: a passepartout to flush the intruder out?Delia Goletti, Elisa Petruccioli, Alessandra Romagnoli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapyStefania Carrara, Donatella Vincenti, Nicola Petrosillo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 4, 2024
Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goalsDelia Goletti, Graeme Meintjes, Bruno B Andrade, et al.
The Journal of Infection|April 26, 2020
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impactFabrizio Cantini, Laura Niccoli, Daniela Matarrese, et al.
Expert Review of Anti-Infective Therapy|June 1, 2018
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugsDelia Goletti, Linda Petrone, Giuseppe Ippolito, et al.
The Journal of Infectious Diseases|September 9, 2006
Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosisDelia Goletti, Ornella Butera, Federica Bizzoni, et al.
Blood|November 26, 2008
Do human gammadelta T cells respond to M tuberculosis protein antigens?Rita Casetti, Angelo Martino, Alessandra Sacchi, et al.
Expert Opinion on Drug Safety|December 23, 2021
Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsFabrizio Cantini, Delia Goletti, Maurizio Benucci, et al.
Pageof 31

Showing results (31-40 of 310) with videos related to

Sort By:
Pageof 31
European Journal of Histochemistry : EJH|June 28, 2019
Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometryTonino Alonzi, Elisa Petruccioli, Valentina Vanini, et al.
Infectious Disease Reports|July 13, 2016
Tuberculosis Biomarkers: From Diagnosis to ProtectionDelia Goletti, Elisa Petruccioli, Simone A Joosten, et al.
Cytokine & Growth Factor Reviews|February 12, 2013
Autophagy in Mycobacterium tuberculosis infection: a passepartout to flush the intruder out?Delia Goletti, Elisa Petruccioli, Alessandra Romagnoli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapyStefania Carrara, Donatella Vincenti, Nicola Petrosillo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 4, 2024
Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goalsDelia Goletti, Graeme Meintjes, Bruno B Andrade, et al.
The Journal of Infection|April 26, 2020
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impactFabrizio Cantini, Laura Niccoli, Daniela Matarrese, et al.
Expert Review of Anti-Infective Therapy|June 1, 2018
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugsDelia Goletti, Linda Petrone, Giuseppe Ippolito, et al.
The Journal of Infectious Diseases|September 9, 2006
Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosisDelia Goletti, Ornella Butera, Federica Bizzoni, et al.
Blood|November 26, 2008
Do human gammadelta T cells respond to M tuberculosis protein antigens?Rita Casetti, Angelo Martino, Alessandra Sacchi, et al.
Expert Opinion on Drug Safety|December 23, 2021
Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsFabrizio Cantini, Delia Goletti, Maurizio Benucci, et al.
Pageof 31